InsidersTradesSigma
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Discover the detailed record of transactions filed by Duncan Barbara Gayle. Director active across 3 companies, notably Halozyme Therapeutics, INC.. Aggregated, 11 reports have been logged. Split: 0 buy · 2 sells. History available since 3 February 2023. The latest transaction was filed on 20 June 2025 (Levée d'options). Regulator: SEC (Form 4). The full history is free.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
11 of 11 declarations
Duncan Barbara Gayle is a declarant associated with Halozyme Therapeutics, INC. as Director, with INTERCEPT PHARMACEUTICALS INC as Chief Financial Officer, and with Atea Pharmaceuticals, Inc. as Director. The record shows 11 filings in total, and within the sampled recent filings the modal transaction nature is Attribution, with dates ranging from 2016-01-05 to 2026-06-23 and cumulative buy and sell amounts of 0.